Introduction {#s1}
============

Cancers in adolescents and young adults (AYAs; 15--29 years) have distinctive characteristics compared with cancers in children and older cohorts.

The incidence pattern of specific cancer types differ between AYAs and younger and older patients. In addition, the genetic and histologic patterns of cancers among AYAs differ from those of older patients [@pone.0096088-Bleyer1]. Because cancer is uncommon among AYAs, this patient population has not drawn public attention compared with the pediatric and adult populations. However, an increase in cancer incidence among AYAs has been reported in Europe [@pone.0096088-Cotterill1]--[@pone.0096088-Birch1] and the United States [@pone.0096088-Bleyer2].

Over 200,000 new cancer patients are diagnosed annually in Korea [@pone.0096088-Jung1], and approximately 3,200 (1.6%) AYAs were diagnosed with cancer in Korea in 2010. According to the U.S. National Cancer Institute Surveillance Epidemiology and End Results (SEER), 2% of all invasive cancers are diagnosed in individuals aged 15--29 years [@pone.0096088-Bleyer2]. Although only a small proportion of all malignancies are diagnosed in AYAs, high-grade and later-stage tumors of certain cancers are more likely to be diagnosed in this patient population [@pone.0096088-Bleyer1]. Furthermore, cancer diagnosis in AYAs can greatly influence future quality of life and life expectancy [@pone.0096088-Bleyer3]. In fact, in Korea, cancer is the leading cause of death among AYAs, after suicide and traffic accidents [@pone.0096088-Statistics1]. However, to the best of our knowledge, cancer incidence and survival among AYAs in Korea have never been studied. Therefore, this study aimed to investigate cancer incidence and survival among AYAs in Korea. We examined the trends in cancer incidence rates from 1999 to 2010 and the trends in relative survival rates from 1993 to 2010 among Korean AYAs.

Materials and Methods {#s2}
=====================

Data Sources {#s2a}
------------

In 1980, the Korean Ministry of Health and Welfare started the Korea Central Cancer Registry (KCCR), a nationwide, hospital-based cancer registry [@pone.0096088-Korea1]. Until 1998, the registry collected cancer cases from more than 180 hospitals in Korea annually, and these data represent 80--90% of all cancer incidence in Korea [@pone.0096088-Shin1]. Since 1999, the KCCR has covered the entire population under the population-based cancer registry program [@pone.0096088-Jung1]. The Korea National Cancer Incidence Database (KNCIDB) KCCR data from 1999 to 2002 and from 2003 to 2007 have been published in Cancer Incidence in Five Continents, which reflects the completeness and validity of the incidence data [@pone.0096088-Cancer1].

Incidence data were collected for Korean AYAs aged 15--29 years who were newly diagnosed with cancer between 1999 and 2010. The incidence data were collected from the KNCIDB of the KCCR and included age, sex, diagnosis date, primary tumor site, morphology, the diagnostic method, and stage at diagnosis.

Survival data for individuals aged 15--29 years who were newly diagnosed with cancer from 1993--2010 were obtained from the KNCIDB, and the patients' vital status was followed until December 31, 2011. The survival analysis was based on the KNCIDB data and mortality data obtained from Statistics Korea.

Case Definition {#s2b}
---------------

In accordance with the guidelines of the National Cancer Institute SEER Program [@pone.0096088-Bleyer2] and the Canadian Cancer Society [@pone.0096088-Canadian1] in this study, AYAs were defined as adolescents and young adults aged 15--29 years.

Cancer sites were coded by primary site and morphology using the International Classification of Diseases for Oncology (third edition) [@pone.0096088-Fritz1]. Cancers were classified according to the SEER AYA scheme, which is based on a modified version of the International Classification of Childhood Cancer [@pone.0096088-Bleyer2]. In particular, the SEER AYA scheme is based on an updated classification proposed by Barr et al. and is composed of ten major groups and second- and third-level subgroups according to the site of origin [@pone.0096088-Barr1].

Incidence {#s2c}
---------

Age-specific incidence rates per million were analyzed in each diagnostic subgroup according to the age at diagnosis (15--19 years, 20--24 years, and 25--29 years), and age-standardized rates (ASRs) according to sex were calculated using the world standard population defined by the World Health Organization [@pone.0096088-Segi1]. Trends in annual ASRs were calculated using the annual percent change (APC), which was estimated using the following formula: 100×(e^β^-1), where β is the slope calculated from a linear regression of log age-standardized incidence rates in a calendar year [@pone.0096088-Howlader1]. The male-to-female (M/F) ratio was the ratio of the ASR among males to the ASR among females. Comparisons of age-standardized incidence rates in males and females were calculated by the direct method [@pone.0096088-Smith1].

Survival {#s2d}
--------

Relative survival rates were estimated according to the time period: 1993--1995, 1996--2000, 2001--2005 and 2006--2010. Relative survival rates according to the diagnostic group were calculated by dividing observed survival by expected survival among comparable groups in the general population [@pone.0096088-Ederer1] using the Ederer II method [@pone.0096088-Ederer2]. These survival rates were estimated using "complete analysis", which included "right-censored" patients. Due to this inclusion of the early survival experience of more recently recruited patients, the analysis provided more up-to-date and precise survival rates in long-term survival [@pone.0096088-Brenner1]. Trends in 5-year relative survival rates were also calculated. Additionally, the effects of sex, diagnostic group, and time period on survival were assessed using a relative excess risk model. All analyses were performed using SAS version 9.2.

Results {#s3}
=======

Incidence {#s3a}
---------

From 1999 to 2010, 39,639 cancer cases (2.3% of all cancer patients) were newly diagnosed in AYAs. Of these cases, 14,016 (35.4%) and 25,623 (64.6%) cases were diagnosed in males and females, respectively. According to the age at diagnosis, 6,396 (16.1%) cases were diagnosed at 15--19 years of age, 10,433 (26.3%) cases were diagnosed at 20--24 years, and 22,810 (26.3%) cases were diagnosed at 25--29 years.

The number of cases per age group (15--19 years, 20--24 years and 25--29 years) by sex, age-specific incidence rates, and age-standardized incidence rates among both males and females and M/F ratios according to the diagnostic group are shown in [Table 1](#pone-0096088-t001){ref-type="table"}.

10.1371/journal.pone.0096088.t001

###### Number of cases, age-specific incidence rates, and age-standardized incidence rates from 1999 to 2010 according to sex and age.

![](pone.0096088.t001){#pone-0096088-t001-1}

  Diagnostic group (SEER)                                                                        Males      Females      Total        M/F                                                                                                                                                                    
  ------------------------------------------------------------------------------------------- ----------- ----------- ----------- ----------- ----------- ----------- ------------ ----------- ----------- ----------- ----------- ----------- ------------ ----------- ------------ ----------- ----------- ------------------------------------------
  **All Cancers**                                                                              **3,249**   **150.9**   **3,891**   **170.7**   **6,876**   **273.4**   **14,016**   **196.4**   **3,147**   **160.4**   **6,542**   **305.6**   **15,934**   **663.3**   **25,623**   **367.8**   **279.9**   **0.5** [†](#nt102){ref-type="table-fn"}
  **All Cancers (excluding thyroid carcinoma)** [‡](#nt103){ref-type="table-fn"}               **3,065**   **142.3**   **3,445**   **151.1**   **5,665**   **225.2**   **12,175**   **171.7**   **2,275**   **115.9**   **3,660**   **171.0**   **8,793**    **366.0**   **14,728**   **213.6**   **192.2**   **0.8** [†](#nt102){ref-type="table-fn"}
  **1. Leukemias**                                                                              **737**    **17.1**     **600**    **13.2**     **694**    **13.8**    **2,031**    **14.8**     **482**    **12.3**     **430**    **10.0**     **549**     **11.4**    **1,461**    **11.3**    **13.1**    **1.3** [†](#nt102){ref-type="table-fn"}
  1.1 Acute lymphoid leukemia                                                                     307         7.1         177         3.9         130         2.6         614          4.6         170         4.3         110         2.6          95          2.0         375          3.0         3.9        1.5[†](#nt102){ref-type="table-fn"}
  1.2 Acute myeloid leukemia                                                                      265        12.3         230        10.1         287        11.4         782         11.3         226        11.5         190         8.9         283         11.8         699         10.8        11.0        1.1[†](#nt102){ref-type="table-fn"}
  1.3 Chronic myeloid leukemia                                                                    96          4.5         131         5.7         187         7.4         414          5.8         37          1.9         75          3.5          92          3.8         204          3.0         4.5        1.9[†](#nt102){ref-type="table-fn"}
  1.4 Other and unspecified leukemia                                                              69          3.2         62          2.7         90          3.6         221          3.2         49          2.5         55          2.6          79          3.3         183          2.8         3.0        1.1[†](#nt102){ref-type="table-fn"}
  **2. Lymphomas**                                                                              **516**    **24.0**     **533**    **23.4**     **612**    **24.3**    **1,661**    **23.9**     **269**    **13.7**     **414**    **19.3**     **568**     **23.6**    **1,251**    **18.7**    **21.4**    **1.3** [†](#nt102){ref-type="table-fn"}
  2.1 Non-Hodgkin lymphoma                                                                        406        18.9         437        19.2         524        20.8        1,367        19.6         199        10.1         314        14.7         461         19.2         974         14.5        17.1        1.4[†](#nt102){ref-type="table-fn"}
  2.2 Hodgkin lymphoma                                                                            110         5.1         96          4.2         88          3.5         294          4.3         70          3.6         100         4.7         107          4.5         277          4.2         4.3                        1.0
  **3. CNS and Other Intracranial and Intraspinal Neoplasms**                                   **332**    **15.4**     **320**    **14.0**     **406**    **16.1**    **1,058**    **15.2**     **228**    **11.6**     **214**    **10.0**     **361**     **15.0**     **803**     **12.2**    **13.8**    **1.2** [†](#nt102){ref-type="table-fn"}
  3.1 Astrocytoma                                                                                 88          4.1         110         4.8         171         6.8         369          5.2         82          4.2         74          3.5         155          6.5         311          4.7         4.9        1.1[†](#nt102){ref-type="table-fn"}
  3.2 Other glioma                                                                                44          2.0         50          2.2         101         4.0         195          2.7         42          2.1         33          1.5          88          3.7         163          2.4         2.6        1.1[†](#nt102){ref-type="table-fn"}
  3.3 Ependymoma                                                                                  23          1.1         24          1.1         33          1.3          80          1.1         15          0.8         21          1.0          22          0.9          58          0.9         1.0        1.3[†](#nt102){ref-type="table-fn"}
  3.4. Medulloblastoma and other PNET                                                             66          3.1         35          1.5         24          1.0         125          1.9         47          2.4         30          1.4          24          1.0         101          1.6         1.8        1.2[†](#nt102){ref-type="table-fn"}
  3.5 Other specified intracranial and intraspinal neoplasms                                      11          0.5          9          0.4         10          0.4          30          0.4          3          0.2          7          0.3          11          0.5          21          0.3         0.4        1.4[†](#nt102){ref-type="table-fn"}
  3.6 Unspecified intracranial and intraspinal neoplasms                                          100         4.6         92          4.0         67          2.7         259          3.8         39          2.0         49          2.3          61          2.5         149          2.3         3.1        1.7[†](#nt102){ref-type="table-fn"}
  **4. Osseous and Chondromatous Neoplasms**                                                    **379**    **17.6**     **219**     **9.6**     **146**     **5.8**     **744**     **11.3**     **189**     **9.6**     **124**     **5.8**     **120**      **5.0**     **433**      **6.9**     **9.2**    **1.6** [†](#nt102){ref-type="table-fn"}
  4.1 Osteosarcoma                                                                                257        11.9         104         4.6         53          2.1         414          6.4         126         6.4         49          2.3          47          2.0         222          3.7         5.1        1.8[†](#nt102){ref-type="table-fn"}
  4.2 Chondrosarcoma                                                                              28          1.3         39          1.7         45          1.8         112          1.6         10          0.5         33          1.5          34          1.4          77          1.1         1.4        1.4[†](#nt102){ref-type="table-fn"}
  4.3 Ewing tumor                                                                                 53          2.5         44          1.9         18          0.7         115          1.7         30          1.5         14          0.7          21          0.9          65          1.0         1.4        1.7[†](#nt102){ref-type="table-fn"}
  4.4 Other specified and unspecified bone tumors                                                 41          1.9         32          1.4         30          1.2         103          1.5         23          1.2         28          1.3          18          0.7          69          1.1         1.3        1.4[†](#nt102){ref-type="table-fn"}
  **5. Soft Tissue Sarcomas**                                                                   **220**    **10.2**     **248**    **10.9**     **345**    **13.7**     **813**     **11.5**     **174**     **8.9**     **223**    **10.4**     **302**     **12.6**     **699**     **10.5**    **11.1**    **1.1** [†](#nt102){ref-type="table-fn"}
  5.1 Fibromatous neoplasms                                                                       44          2.0         63          2.8         92          3.7         199          2.8         35          1.8         59          2.8          88          3.7         182          2.7         2.7                        1.0
  5.2 Rhabdomyosarcoma                                                                            58          2.7         26          1.1         25          1.0         109          1.7         36          1.8         16          0.7          19          0.8          71          1.2         1.4        1.4[†](#nt102){ref-type="table-fn"}
  5.3 Other soft tissue sarcoma                                                                   118         5.5         159         7.0         228         9.1         505          7.1         103         5.2         148         6.9         195          8.1         446          6.7         6.9        1.1[†](#nt102){ref-type="table-fn"}
  **6. Germ Cell and Trophoblastic Neoplasms**                                                  **340**    **15.8**     **417**    **18.3**     **473**    **18.8**    **1,230**    **17.6**     **341**    **17.4**     **300**    **14.0**     **295**     **12.3**     **936**     **14.7**    **16.1**    **1.2** [†](#nt102){ref-type="table-fn"}
  6.1 Germ cell and trophoblastic neoplasms of gonads                                             84          3.9         231        10.1         364        14.5         679          9.3         283        14.4         243        11.4         195          8.1         721         11.4        10.3        0.8[†](#nt102){ref-type="table-fn"}
  6.2 Germ cell and trophoblastic neoplasms of nongonadal sites                                   256        11.9         186         8.2         109         4.3         551          8.3         58          3.0         57          2.7         100          4.2         215          3.2         5.9        2.5[†](#nt102){ref-type="table-fn"}
  **7. Melanoma and Skin Carcinomas**                                                           **21**      **1.0**     **40**      **1.8**     **107**     **4.3**     **168**      **2.3**     **19**      **1.0**     **42**      **2.0**      **98**      **4.1**     **159**      **2.3**     **2.3**                    **1.0**
  7.1 Melanoma                                                                                    12          0.6         20          0.9         50          2.0          82          1.1         11          0.6         26          1.2          46          1.9          83          1.2         1.2                        0.9
  7.2 Skin carcinomas                                                                              9          0.4         20          0.9         57          2.3          86          1.2          8          0.4         16          0.7          52          2.2          76          1.1         1.1                        1.1
  **8. Carcinomas**                                                                             **516**    **24.0**    **1,272**   **55.8**    **3,653**   **145.2**   **5,441**    **73.0**    **1,257**   **64.1**    **4,451**   **207.9**   **12,959**   **539.4**   **18,667**   **262.2**   **165.0**   **0.3** [†](#nt102){ref-type="table-fn"}
  8.1 Thyroid carcinoma                                                                           184         8.5         446        19.6        1,211       48.1        1,841        24.7         872        44.4        2,882       134.6       7,141        297.3       10,895       154.2       87.7        0.2[†](#nt102){ref-type="table-fn"}
  8.2 Other carcinoma of head and neck                                                            81          3.8         133         5.8         213         8.5         427          5.9         72          3.7         133         6.2         199          8.3         404          6.0         5.9                        1.0
  8.2.1 Nasopharyngeal carcinoma                                                                  40          1.9         43          1.9         47          1.9         130          1.9         17          0.9         19          0.9          28          1.2          64          1.0         1.4        1.9[†](#nt102){ref-type="table-fn"}
  8.2.2 Other sites in lip, oral cavity, and pharynx                                              36          1.7         81          3.6         143         5.7         260          3.6         47          2.4         104         4.9         152          6.3         303          4.4         4.0                        0.8
  8.2.3 Nasal cavity, middle ear, sinuses, larynx, and other ill-defined sites in head/neck        5          0.2          9          0.4         23          0.9          37          0.5          8          0.4         10          0.5          19          0.8          37          0.5         0.5                        1.0
  8.3 Carcinoma of trachea, bronchus, and lung                                                    25          1.2         50          2.2         104         4.1         179          2.4         16          0.8         52          2.4         121          5.0         189          2.7         2.6        0.9[†](#nt102){ref-type="table-fn"}
  8.4 Carcinoma of breast                                                                                                  2          0.1          3          0.1          5           0.1         15          0.8         265        12.4        1,672        69.6        1,952        26.5        13.0       0.003[†](#nt102){ref-type="table-fn"}
  8.5 Carcinoma of genitourinary tract                                                            30          1.4         93          4.1         290        11.5         413          5.5         154         7.8         524        24.5        1,986        82.7        2,664        37.1        20.9        0.1[†](#nt102){ref-type="table-fn"}
  8.5.1 Carcinoma of kidney                                                                       17          0.8         52          2.3         173         6.9         242          3.2         18          0.9         34          1.6         108          4.5         160          2.3         2.8        1.4[†](#nt102){ref-type="table-fn"}
  8.5.2 Carcinoma of bladder                                                                      12          0.6         30          1.3         103         4.1         145          1.9          2          0.1         16          0.7          31          1.3          49          0.7         1.3        2.8[†](#nt102){ref-type="table-fn"}
  8.5.3 Carcinoma of gonads                                                                       \-          \-           3          0.1          2          0.1          5           0.1         123         6.3         242        11.3         420         17.5         785         11.5         5.6        0.01[†](#nt102){ref-type="table-fn"}
  8.5.4 Carcinoma of cervix and uterus                                                            \-          \-          \-          \-          \-          \-           \-          \-           8          0.4         229        10.7        1,399        58.2        1,636        22.2        10.8                         \-
  8.5.5 Carcinoma of other and ill-defined sites in genitourinary tract                            1          0.0          8          0.4         12          0.5          21          0.3          3          0.2          3          0.1          28          1.2          34          0.5         0.4        0.6[†](#nt102){ref-type="table-fn"}
  8.6 Carcinoma of gastrointestinal tract                                                         161         7.5         500        21.9        1,715       68.2        2,376        31.5         113         5.8         553        25.8        1,740        72.4        2,406        33.5        32.5        0.9[†](#nt102){ref-type="table-fn"}
  8.6.1 Carcinoma of colon and rectum                                                             67          3.1         176         7.7         530        21.1         773         10.3         46          2.3         165         7.7         402         16.7         613          8.7         9.5        1.2[†](#nt102){ref-type="table-fn"}
  8.6.2 Carcinoma of stomach                                                                      41          1.9         179         7.9         764        30.4         984         12.9         33          1.7         298        13.9        1,116        46.5        1,447        19.9        16.3        0.6[†](#nt102){ref-type="table-fn"}
  8.6.3 Carcinoma of liver and intrahepatic bile ducts                                            51          2.4         121         5.3         373        14.8         545          7.3         18          0.9         66          3.1         151          6.3         235          3.3         5.4        2.2[†](#nt102){ref-type="table-fn"}
  8.6.4 Carcinoma of pancreas                                                                      1          0.0         16          0.7         21          0.8          38          0.5         12          0.6         14          0.7          32          1.3          58          0.9         0.7        0.6[†](#nt102){ref-type="table-fn"}
  8.6.5 Carcinoma of other and ill-defined sites in gastrointestinal tract                         1          0.0          8          0.4         27          1.1          36          0.5          4          0.2         10          0.5          39          1.6          53          0.7         0.6        0.6[†](#nt102){ref-type="table-fn"}
  8.7 Carcinoma of other and ill-defined sites                                                    35          1.6         48          2.1         117         4.7         200          2.7         15          0.8         42          2.0         100          4.2         157          2.2         2.5        1.2[†](#nt102){ref-type="table-fn"}
  8.7.1 Adrenocortical carcinoma                                                                   1          0.0          5          0.2          6          0.2          12          0.2          3          0.2          7          0.3          8           0.3          18          0.3         0.2        0.6[†](#nt102){ref-type="table-fn"}
  8.7.2 Carcinoma of other and ill-defined sites, NOS                                             34          1.6         43          1.9         111         4.4         188          2.6         12          0.6         35          1.6          92          3.8         139          2.0         2.3        1.3[†](#nt102){ref-type="table-fn"}
  **9. Miscellaneous Specified Neoplasms, NOS**                                                 **120**     **5.6**     **117**     **5.1**     **181**     **7.2**     **418**      **6.0**     **100**     **5.1**     **141**     **6.6**     **254**     **10.6**     **495**      **7.3**     **6.6**    **0.8** [†](#nt102){ref-type="table-fn"}
  9.1 Other pediatric and embryonal tumors, NOS                                                   30          1.4         20          0.9         24          1.0          74          1.1         20          1.0         17          0.8          22          0.9          59          0.9         1.0        1.2[†](#nt102){ref-type="table-fn"}
  9.2 Other specified and embryonal tumors, NOS                                                   90          4.2         97          4.3         157         6.2         344          4.9         80          4.1         124         5.8         232          9.7         436          6.4         5.6        0.8[†](#nt102){ref-type="table-fn"}
  **10. Unspecified Malignant Neoplasms**                                                       **67**      **3.1**     **125**     **5.5**     **259**    **10.3**     **451**      **6.2**     **88**      **4.5**     **203**     **9.5**     **428**     **17.8**     **719**     **10.4**     **8.2**    **0.6** [†](#nt102){ref-type="table-fn"}

\*M/F Ratio  =  Male ASR/Female ASR.

P-values \<0.05.

Thyroid carcinoma was excluded from the calculation of the incidence rate of all cancers combined because of its unusually high incidence rate.

CR, crude incidence rate; CNS, central nervous system; PNET, primitive neuroectodermal tumor; NOS, not otherwise specified.

Between 1999 and 2010, the overall age-standardized incidence rate of cancers among AYAs in Korea was 279.9 per million. Cancer incidence was higher in females (367.8 per million) than in males (196.4 per million), and for all cancers combined, the male/female ratio was 0.5 (*P*\<0.05). The higher rate among females was largely due to a much higher incidence rate of thyroid carcinomas (24.7 per million among males vs. 154.2 per million among females). Because the incidence rate of thyroid carcinoma was unusually high, the age-standardized incidence rates of all cancers combined were recalculated, excluding thyroid carcinoma (group 8.1). Removing thyroid carcinomas, the overall ASR of cancers was 192.2 per million (171.7 per million for males and 213.6 per million for females) ([Table 1](#pone-0096088-t001){ref-type="table"}).

The incidence increased with age, from 150.9 in males and 160.4 in females per million at 15--19 years of age to 170.7 in males and 305.6 in females per million, respectively, at 20--24 years of age. The incidence further increased at 25--59 years of age, to 273.4 in males and 663.3 in females per million, respectively ([Table 1](#pone-0096088-t001){ref-type="table"}). The incidence rates were correlated with age group for most subtypes, with the notable exceptions of leukemia and osseous/chondromatous neoplasms, which were more common among younger AYAs ([Table 1](#pone-0096088-t001){ref-type="table"}).

[Table 2](#pone-0096088-t002){ref-type="table"} shows the secular trends in cancer incidence among AYAs from 1999 to 2010 according to the diagnostic group. The incidence rate of all cancers among AYAs significantly increased, from 208.7 per million in 1999 to 396.4 per million in 2010 (APC = 6.3%; *P*\<0.05). Over the studied time period, there was also a steady increase in the incidence of cancer among AYAs for both males (APC = 3.9%) and females (APC = 7.8%) ([Figure 1](#pone-0096088-g001){ref-type="fig"}).

![Annual percent change (APC) from 1999--2010 according to the diagnostic group (SEER).](pone.0096088.g001){#pone-0096088-g001}
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###### Trends in age-standardized incidence rates among Korean AYAs and estimated annual percent changes (APCs).

![](pone.0096088.t002){#pone-0096088-t002-2}

                                                                                1999    2000    2001    2002    2003    2004    2005    2006    2007    2008    2009    2010                     APC
  ---------------------------------------------------------------------------- ------- ------- ------- ------- ------- ------- ------- ------- ------- ------- ------- ------- ----------------------------------------
  All cancers                                                                   208.7   204.7   230.3   226.4   256.3   266.2   275.6   290.8   315.8   355.6   370.4   396.4    6.3[\*](#nt105){ref-type="table-fn"}
  All cancers (excluding thyroid carcinoma) [†](#nt106){ref-type="table-fn"}    174.8   170.9   188.2   178.9   193.6   188.0   193.5   197.1   203.8   210.7   208.2   207.5    1.8[\*](#nt105){ref-type="table-fn"}
  **1 Leukemias**                                                               23.4    24.1    27.8    26.0    24.5    24.5    25.6    26.6    28.2    29.6    28.9    26.5     1.5[\*](#nt105){ref-type="table-fn"}
  1.1 Acute lymphoid leukemia                                                    7.0     7.6     7.4     7.2     6.7     6.9     7.7     8.0     8.4     8.3     8.9     8.8     2.2[\*](#nt105){ref-type="table-fn"}
  1.2 Acute myeloid leukemia                                                    10.4     9.2    12.3    12.2    10.5    10.5    10.8    12.5    11.3    12.7    11.1     9.3                     0.3
  1.3 Chronic myeloid leukemia                                                   3.5     4.3     4.7     3.7     4.7     4.4     4.5     3.6     4.9     5.0     5.3     5.5     2.9[\*](#nt105){ref-type="table-fn"}
  1.4 Other and unspecified leukemia                                             2.5     3.0     3.4     2.8     2.7     2.6     2.7     2.5     3.6     3.5     3.6     2.8                     1.5
  **2 Lymphomas**                                                               16.6    15.0    17.7    17.2    21.8    23.1    21.5    23.9    23.9    26.7    26.3    26.0     5.3[\*](#nt105){ref-type="table-fn"}
  2.1 Non-Hodgkin lymphoma                                                      14.5    12.5    14.4    13.6    17.2    18.2    17.7    19.6    18.6    20.7    20.8    19.9     4.5[\*](#nt105){ref-type="table-fn"}
  2.2 Hodgkin lymphoma                                                           2.1     2.4     3.3     3.6     4.6     4.9     3.8     4.3     5.3     6.0     5.5     6.1     9.1[\*](#nt105){ref-type="table-fn"}
  **3 CNS and Other Intracranial and Intraspinal Neoplasms (all behaviors)**    12.7    12.9    12.0    13.4    15.0    14.5    12.9    14.6    14.5    15.7    14.1    13.3                     1.2
  3.1. Astrocytoma                                                               4.8     3.8     4.7     4.5     4.7     5.4     4.6     5.0     6.3     5.6     4.8     5.3     2.3[\*](#nt105){ref-type="table-fn"}
  3.2 Other glioma                                                               1.4     1.8     1.5     2.8     2.8     2.5     2.5     2.6     2.7     4.2     3.3     3.4     8.0[\*](#nt105){ref-type="table-fn"}
  3.3 Ependymoma                                                                 0.5     1.0     1.1     0.9     1.1     0.9     0.7     1.2     1.0     1.4     1.2     1.3     4.9[\*](#nt105){ref-type="table-fn"}
  3.4. Medulloblastoma and other PNET                                            1.6     1.5     1.6     2.0     2.3     2.3     1.2     2.4     1.3     2.0     2.0     1.1                     -0.8
  3.5 Other specified intracranial and intraspinal neoplasms                     0.6     0.4     0.4     0.2     0.5     0.4     0.3     0.2     0.5     0.5     0.2     0.3                     -3.9
  3.6 Unspecified intracranial and intraspinal neoplasms                         3.7     4.5     2.8     3.0     3.7     2.9     3.6     3.1     2.8     2.0     2.5     2.1    -5.0[\*](#nt105){ref-type="table-fn"}
  **4 Osseous & Chondromatous Neoplasms**                                        8.4     8.7    11.4     7.9    10.6     8.5     8.2     7.6     9.7    10.2     8.8    10.5                     0.6
  4.1 Osteosarcoma                                                               5.0     4.9     6.8     4.9     5.6     5.3     4.9     3.8     4.4     6.1     4.4     5.2                     -1.1
  4.2 Chondrosarcoma                                                             1.4     1.4     1.1     0.9     1.9     1.0     1.3     1.1     1.5     1.6     1.2     2.0                     2.3
  4.3 Ewing tumor                                                                0.7     1.3     1.7     1.2     1.4     1.0     1.2     1.3     1.9     1.3     1.9     2.1     5.8[\*](#nt105){ref-type="table-fn"}
  4.4 Other specified and unspecified bone tumors                                1.3     1.1     1.8     0.9     1.7     1.1     0.8     1.5     1.9     1.2     1.3     1.2                     0.4
  **5 Soft Tissue Sarcomas**                                                     8.9     8.5    10.6     9.5    11.0    10.9     9.7    12.5    13.0    12.9    13.6    12.8     4.1[\*](#nt105){ref-type="table-fn"}
  5.1 Fibromatous neoplasms                                                      1.4     1.8     1.7     2.0     3.2     2.7     2.5     3.3     3.2     4.5     3.1     4.2     9.6[\*](#nt105){ref-type="table-fn"}
  5.2 Rhabdomyosarcoma                                                           1.2     1.6     1.2     1.6     0.6     2.5     1.3     2.4     1.5     0.7     1.0     1.3                     -1.6
  5.3 Other soft tissue sarcoma                                                  6.3     5.0     7.7     5.9     7.2     5.7     5.9     6.8     8.3     7.7     9.4     7.3     3.2[\*](#nt105){ref-type="table-fn"}
  **6 Germ Cell and Trophoblastic Neoplasms**                                   13.5    14.0    14.8    14.3    14.5    14.7    17.0    16.4    19.1    17.8    18.3    20.2     3.6[\*](#nt105){ref-type="table-fn"}
  6.1 Germ cell and trophoblastic neoplasms of gonads                            9.1     8.6     9.9     9.0     9.0    10.2    10.3    10.3    11.2    12.0    11.4    12.9     3.3[\*](#nt105){ref-type="table-fn"}
  6.2 Germ cell and trophoblastic neoplasms of nongonadalsites                   4.4     5.5     4.9     5.3     5.6     4.4     6.7     6.1     8.0     5.9     7.0     7.3     4.2[\*](#nt105){ref-type="table-fn"}
  **7 Melanoma and Skin Carcinomas**                                             1.7     2.1     2.6     1.8     1.0     1.5     3.7     2.5     2.3     2.7     3.2     2.5                     4.8
  7.1 Melanoma                                                                   1.1     1.2     1.2     0.9     0.5     0.9     2.0     0.9     0.9     1.4     1.9     1.1                     2.6
  7.2 Skin carcinomas                                                            0.6     0.8     1.5     0.9     0.6     0.5     1.7     1.6     1.4     1.3     1.4     1.5     7.2[\*](#nt105){ref-type="table-fn"}
  **8 Carcinomas**                                                              105.3   102.0   116.4   123.2   141.5   155.2   163.7   173.1   191.8   225.1   244.4   270.7    9.4[\*](#nt105){ref-type="table-fn"}
  8.1 Thyroid carcinoma                                                         33.9    33.8    42.1    47.4    62.6    78.2    82.1    93.6    112.0   144.9   162.2   188.9   17.9[\*](#nt105){ref-type="table-fn"}
  8.2 Other carcinoma of head and neck                                           4.9     5.1     5.0     5.9     6.7     5.9     6.1     5.3     6.8     6.7     8.1     5.2                     2.5
  8.2.1 Nasopharyngeal carcinoma                                                 1.1     1.8     1.2     1.2     1.9     1.6     1.3     1.1     1.4     1.7     1.8     1.4                     1.2
  8.2.2 Other sites in lip, oral cavity and pharynx                              3.2     3.0     3.3     4.2     3.9     3.8     4.4     3.9     5.0     4.4     5.5     3.6     3.4[\*](#nt105){ref-type="table-fn"}
  8.2.3 Nasal cav,mid ear,sinuses,larynx,oth ill-defhead/neck                    0.6     0.4     0.4     0.5     0.9     0.6     0.4     0.3     0.5     0.7     0.7     0.3                     -0.6
  8.3 Carcinoma of trachea,bronchus, and lung                                    2.4     1.5     2.9     2.2     2.5     3.0     3.1     3.0     1.9     2.2     2.9     3.4                     2.6
  8.4 Carcinoma of breast                                                        8.5    11.4    12.3    13.6    12.2    12.6    15.1    13.8    13.9    14.1    13.8    15.3     3.5[\*](#nt105){ref-type="table-fn"}
  8.5 Carcinoma of genitourinary tract                                          18.4    14.7    17.2    18.7    21.5    21.1    20.9    23.8    22.2    24.5    24.0    25.7     4.2[\*](#nt105){ref-type="table-fn"}
  8.5.1 Carcinoma of kidney                                                      2.2     0.9     2.3     2.1     2.1     2.8     2.5     4.2     2.4     4.3     4.4     3.3     9.1[\*](#nt105){ref-type="table-fn"}
  8.5.2 Carcinoma of bladder                                                     1.4     0.8     1.4     1.1     1.7     1.5     1.8     1.1     1.6     1.2     0.9     1.4                     0.7
  8.5.3 Carcinoma of gonads                                                      5.9     5.9     4.9     5.5     6.8     5.2     5.8     5.2     6.4     4.9     4.4     6.1                     -0.8
  8.5.4 Carcinoma of cervix and uterus                                           8.6     6.7     8.4     9.5    10.3    11.1    10.3    13.0    11.3    13.9    13.7    14.6     6.2[\*](#nt105){ref-type="table-fn"}
  8.5.5 Carc of other and ill-def sites, geniourinary tract                      0.2     0.3     0.2     0.5     0.5     0.4     0.5     0.3     0.5     0.2     0.5     0.3                     2.8
  8.6 Carcinoma of gastrointestinal tract                                       34.2    32.3    34.2    33.1    34.3    31.6    34.0    31.2    31.7    31.1    31.1    30.4    -1.0[\*](#nt105){ref-type="table-fn"}
  8.6.1 Carcinoma of colon and rectum                                            9.1     8.1     8.4     7.7     9.1     8.3     9.2     9.4     9.8    12.9    11.8    11.3     3.7[\*](#nt105){ref-type="table-fn"}
  8.6.2 Carcinoma of stomach                                                    18.8    17.3    18.4    18.7    17.4    15.8    17.3    15.4    15.3    13.2    13.7    13.2    -3.3[\*](#nt105){ref-type="table-fn"}
  8.6.3 Carcinoma of liver and intrahepatic bile ducts                           5.2     5.5     6.8     5.8     6.3     5.4     6.0     5.2     5.3     3.6     4.3     4.5    -3.2[\*](#nt105){ref-type="table-fn"}
  8.6.4 Carcinoma of pancreas                                                    0.4     0.8     0.3     0.6     0.6     1.0     0.8     0.8     0.8     0.6     0.4     1.1                     4.8
  8.6.5 Carc other and ill-def sites, gastrointestinal tract                     0.7     0.6     0.4     0.2     0.8     1.0     0.6     0.4     0.6     0.8     1.0     0.3                     0.1
  8.7 Carcinoma of other and ill-def sites                                       3.0     3.3     2.7     2.3     1.8     2.8     2.4     2.5     3.1     1.7     2.4     2.0                     -3.0
  8.7.1 Adrenocortical carcinoma                                                 0.2     0.2     0.1     0.2     0.2     0.1     0.1     0.4     0.5     0.1     0.4     \-                      6.7
  8.7.2 Carcinoma of other and ill-defined sites, NOS                            2.8     3.0     2.6     2.1     1.6     2.7     2.3     2.1     2.6     1.6     1.9     2.0    -3.4[\*](#nt105){ref-type="table-fn"}
  **9 Miscellaneous specified neoplasms, NOS**                                   3.1     4.4     4.3     4.3     7.5     6.4     7.5     8.2     8.2     9.7     8.1     9.1     9.8[\*](#nt105){ref-type="table-fn"}
  9.1 Other pediatric and embryonal tumors, NOS                                  0.7     1.3     0.7     0.8     1.4     0.6     1.3     0.9     0.9     1.5     0.7     1.4                     3.0
  9.2 Other specified and embryonal tumors, NOS                                  2.5     3.1     3.6     3.5     6.0     5.8     6.3     7.4     7.3     8.3     7.4     7.7                     11.3
  **10 Unspecified Malignant Neoplasms**                                        15.1    13.1    12.7     8.8     8.8     7.1     5.6     5.3     5.0     5.1     4.6     4.7    -10.9[\*](#nt105){ref-type="table-fn"}

\**P*-values \<0.05.

Thyroid carcinoma was excluded from the calculation of the incidence rate of all cancers combined because of its unusually high incidence rate.

AYAs, adolescents and young adults (aged 15--29 years); CNS, central nervous system; PNET, primitive neuroectodermal tumor; NOS, not otherwise specified.

Most cancer sites showed a trend of increasing incidence, with the exception of unspecified malignant neoplasms (group 10) among AYAs (APC  =  −10.9%). For miscellaneous specified neoplasms, NOS (group 9), a rapid increase in the incidence rate was observed for both sexes (APC = 9.8%), but the number of cases was small. For carcinomas (group 10), a large increase in the incidence rate was also observed among AYAs (APC = 9.4%). In particular, among carcinomas, the incidence of thyroid carcinoma showed the most rapid increase (APC = 17.9%; *P*\<0.05). The annual percent change in all cancer combined, excluding thyroid carcinoma, was 1.8% (*P\<*0.05) among AYAs ([Table 2](#pone-0096088-t002){ref-type="table"}), with 1.9% (*P*\<0.05) for males and 1.8% (*P*\<0.05) for females (data not shown). Although the incidence of kidney carcinoma also exhibited a notable increase (APC = 9.1%), the number of cases was small.

The incidence of lymphomas (group 2) exhibited a large increase among AYAs (APC = 5.3%, *P*\<0.05). In particular, Hodgkin lymphoma rapidly increased in incidence (APC = 9.1%, *P*\<0.05) ([Table 2](#pone-0096088-t002){ref-type="table"}).

Cancer incidence trends within diagnostic groups were observed to differ by gender. Among males, the incidence of most cancer sites was increased. Miscellaneous specified neoplasms, NOS, showed the largest increase in incidence (APC = 12.9%, *P*\<0.05), followed by germ cell and trophoblastic neoplasms (APC = 6.9%, *P*\<0.05). Among females, the incidence of most cancer sites was also increased. Carcinomas (APC  = 10.7%, *P*\<0.05) and miscellaneous specified neoplasms, NOS (APC = 7.6%, *P*\<0.05), showed the greatest increases. However, osseous/chondromatous neoplasms (APC  =  −0.5%) and germ cell and trophoblastic neoplasms (APC  =  −0.4%) slightly decreased in incidence ([Figure 1](#pone-0096088-g001){ref-type="fig"}). Additionally, a notable increase in the incidence of carcinomas among females was observed in the cervix (APC = 6.2%, *P*\<0.05) and breast (APC = 3.5%, *P*\<0.05) (data not shown).

Survival {#s3b}
--------

A total of 52,077 cancer cases diagnosed from 1993 to 2010 were used for the survival analysis. [Table 3](#pone-0096088-t003){ref-type="table"} shows the 5-year relative survival rates and numbers of cases in the four time periods (1993--1995, 1996--2000, 2001--2005 and 2006--2010). For all cancers combined, the 5-year relative survival rate of AYAs significantly improved, from 58.9% in 1993--1995 to 84.8% in 2006--2010 (*P*\<0.05). AYAs with leukemia and lymphoma showed the most marked improvement in survival from 25.8% (95% CI: 22.9--28.7) and 55.4% (95% CI: 50.6--59.9) in 1993--1995 to 58.8% (95% CI: 55.5--61.8) and 83.6% (95% CI: 80.9--85.9) in 2006--2010, respectively. Conversely, decreases in survival were observed from 1993--1995 to 2006--2010 for other glioma (group 3.2), carcinoma of gonads (group 8.5.3), and carcinoma of pancreas (group 8.6.4) ([Table 3](#pone-0096088-t003){ref-type="table"}).
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###### Five-year RSRs for Korean AYAs according to the time period of cancer diagnosis**.**

![](pone.0096088.t003){#pone-0096088-t003-3}

  Diagnostic group (SEER)                                                                     Both sexes   Change[†](#nt109){ref-type="table-fn"}      *P*                                                                            
  ------------------------------------------------------------------------------------------ ------------ ---------------------------------------- ------------ ---------- ------------ ---------- ------------ ---------- ---------- -----------------------------------
  **All Cancers**                                                                             **6,387**                   **58.9**                  **12,453**   **66.4**   **14,310**   **76.5**   **18,927**   **84.8**   **25.9**   [\*](#nt108){ref-type="table-fn"}
  **All Cancers (excluding thyroid carcinoma)** [‡](#nt110){ref-type="table-fn"}              **5,525**                   **52.6**                  **10,474**   **60.2**   **10,555**   **68.2**   **10,884**   **74.4**   **21.8**   [\*](#nt108){ref-type="table-fn"}
  **1. Leukemias**                                                                             **866**                    **25.8**                  **1,440**    **35.9**   **1,397**    **47.7**   **1,435**    **58.8**   **33.0**   [\*](#nt108){ref-type="table-fn"}
  1.1 Acute lymphoid leukemia                                                                    237                        19.9                       433          29         379         33.9        425         48.6       28.7     [\*](#nt108){ref-type="table-fn"}
  1.2 Acute myeloid leukemia                                                                     375                        26.0                       602         37.5        624         47.2        588         52.7       26.7     [\*](#nt108){ref-type="table-fn"}
  1.3 Chronic myeloid leukemia                                                                   141                        41.4                       251         51.2        252          76         262         90.5       49.1     [\*](#nt108){ref-type="table-fn"}
  1.4 Other and unspecified leukemia                                                             113                        17.8                       154         24.1        142          36         160         58.8       41.0     [\*](#nt108){ref-type="table-fn"}
  **2. Lymphomas**                                                                             **439**                    **55.4**                   **937**      **65**    **1,133**    **75.8**   **1,315**    **83.6**   **28.2**   [\*](#nt108){ref-type="table-fn"}
  2.1 Non-Hodgkin lymphoma                                                                       372                        51.3                       790         60.6        906         72.5       1,037        82.0       30.7     [\*](#nt108){ref-type="table-fn"}
  2.2 Hodgkin lymphoma                                                                            67                        78.0                       147         88.8        227         88.8        278         89.4       11.4     [\*](#nt108){ref-type="table-fn"}
  **3. CNS and Other Intracranial and Intraspinal Neoplasms**                                  **371**                    **53.4**                   **689**     **54.5**    **730**      **60**     **750**     **65.6**   **12.2**   [\*](#nt108){ref-type="table-fn"}
  3.1. Astrocytoma                                                                               179                        43.2                       305         45.1        275         45.2        291         54.3       11.1     [\*](#nt108){ref-type="table-fn"}
  3.2 Other glioma                                                                                65                        72.7                        83         61.7        141         66.1        177         71.2       -1.5    
  3.3 Ependymoma                                                                                  14                        86.1                        49         79.9         57         88.0         62         87.0       0.9     
  3.4 Medulloblastoma and other PNET                                                              18                        44.6                        84          49          92         47.9         84         52.3       7.7     
  3.5 Other specified intracranial and intraspinal neoplasms                                      13                        61.9                        27         74.4         20         80.2         18         72.6       10.7    
  3.6 Unspecified intracranial and intraspinal neoplasms                                          82                        55.2                       141         61.2        145         76.1        118         80.6       25.4     [\*](#nt108){ref-type="table-fn"}
  **4. Osseous and Chondromatous Neoplasms**                                                   **262**                    **48.3**                   **516**     **66.1**    **479**     **68.7**    **447**     **74.8**   **26.5**   [\*](#nt108){ref-type="table-fn"}
  4.1 Osteosarcoma                                                                               160                        43.3                       305         65.5        281         65.3        231         72.2       28.9     [\*](#nt108){ref-type="table-fn"}
  4.2 Chondrosarcoma                                                                              28                        64.6                        75         87.0         69         87.2         77         94.9       30.3     [\*](#nt108){ref-type="table-fn"}
  4.3 Ewing tumor                                                                                 30                        40.2                        66         39.5         67         52.4         72         51.0       10.8    
  4.4 Other specified and unspecified bone tumors                                                 44                        61.7                        70         71.7         62         80.9         67         85.5       23.8     [\*](#nt108){ref-type="table-fn"}
  **5. Soft Tissue Sarcomas**                                                                  **243**                    **58.7**                   **481**     **58.8**    **554**     **67.5**    **617**     **73.4**   **14.7**   [\*](#nt108){ref-type="table-fn"}
  5.1 Fibromatous neoplasms                                                                       51                        78.8                       103          78         135         93.6        193         95.1       16.3     [\*](#nt108){ref-type="table-fn"}
  5.2 Rhabdomyosarcoma                                                                            32                        28.3                        73         37.1         66         34.9         55         37.5       9.2     
  5.3 Other soft tissue sarcoma                                                                  160                        58.4                       305         57.6        353         63.6        369         67.8       9.4      [\*](#nt108){ref-type="table-fn"}
  **6. Germ Cell and Trophoblastic Neoplasms**                                                 **278**                    **81.6**                   **745**      **87**     **842**     **89.9**    **936**     **91.7**   **10.1**   [\*](#nt108){ref-type="table-fn"}
  6.1 Germ cell and trophoblastic neoplasms of gonads                                            174                        89.4                       465         92.3        558         94.3        613         96.2       6.8      [\*](#nt108){ref-type="table-fn"}
  6.2 Germ cell and trophoblastic neoplasms of nongonadal sites                                  104                        68.6                       280         78.1        284         81.2        323         83.2       14.6    
  **7. Melanoma and Skin Carcinomas**                                                           **56**                    **64.6**                   **111**     **59.7**    **122**     **77.3**    **138**     **86.3**   **21.7**   [\*](#nt108){ref-type="table-fn"}
  7.1 Melanoma                                                                                    25                        32.2                        64         43.9         63         60.5         59         65.0       32.8     [\*](#nt108){ref-type="table-fn"}
  7.2 Skin carcinomas                                                                             31                        90.8                        47         81.2         59         95.2         79         99.0       8.2      [\*](#nt108){ref-type="table-fn"}
  **8. Carcinomas**                                                                           **3,205**                   **67.5**                  **6,607**    **72.2**   **8,366**    **82.4**   **12,601**   **89.9**   **22.4**   [\*](#nt108){ref-type="table-fn"}
  8.1 Thyroid carcinoma                                                                          862                        99.3                      1,979        99.6       3,755        99.9       8,043        99.9       0.6      [\*](#nt108){ref-type="table-fn"}
  8.2 Other carcinoma of head and neck                                                           140                        69.6                       289         77.8        339         83.1        333         85.5       15.9     [\*](#nt108){ref-type="table-fn"}
  8.2.1 Nasopharyngeal carcinoma                                                                  40                        70.4                       104         65.7         79         80.0         75         85.1       14.7     [\*](#nt108){ref-type="table-fn"}
  8.2.2 Other sites in lip, oral cavity, and pharynx                                              73                        79.8                       159         87.7        233         85.6        235         88.6       8.8     
  8.2.3 Nasal cavity, middle ear, sinuses,larynx, and other ill-defined sites in head/neck        27                        41.0                        26         65.6         27         70.6         23         60.5       19.5    
  8.3 Carcinoma of trachea, bronchus, and lung                                                    73                        24.8                       136         36.2        144         47.4        132         43.1       18.3     [\*](#nt108){ref-type="table-fn"}
  8.4 Carcinoma of breast                                                                        310                        68.0                       691         77.2        825         82.0        841         86.5       18.5     [\*](#nt108){ref-type="table-fn"}
  8.5 Carcinoma of genitourinary tract                                                           602                        85.3                      1,191        85.5       1,194        88.9       1,371        86.5       1.2     
  8.5.1 Carcinoma of kidney                                                                       35                        68.9                        94         76.9        142         87.6        209         87.0       18.1     [\*](#nt108){ref-type="table-fn"}
  8.5.2 Carcinoma of bladder                                                                      39                        85.1                        77         94.0         90         93.6         73         95.9       10.8    
  8.5.3 Carcinoma of gonads                                                                      234                        86.6                       396         84.5        326         88.2        291         82.7       -3.9    
  8.5.4 Carcinoma of cervix and uterus                                                           285                        86.6                       605         86.7        611         89.1        781         87.0       0.4     
  8.5.5 Carcinoma of other and ill-defined sites,genitourinary tract                              9                         78.3                        19         79.2         25         84.2         17         88.1       9.8     
  8.6 Carcinoma of gastrointestinal tract                                                       1,123                       38.0                      2,127        42.3       1,974        50.2       1,766        59.2       21.2     [\*](#nt108){ref-type="table-fn"}
  8.6.1 Carcinoma of colon and rectum                                                            246                        47.0                       527         52.8        500         63.2        603         73.9       26.9     [\*](#nt108){ref-type="table-fn"}
  8.6.2 Carcinoma of stomach                                                                     723                        36.3                      1,239        41.4       1,091        49.0        831         58.2       21.9     [\*](#nt108){ref-type="table-fn"}
  8.6.3 Carcinoma of liver andintrahepatic bile ducts                                             90                        23.5                       277         23.6        308         33.6        256         31.6       8.1      [\*](#nt108){ref-type="table-fn"}
  8.6.4 Carcinoma of pancreas                                                                     30                        56.9                        35         57.3         39         59.1         42         43.8      -13.1    
  8.6.5 Carcinoma of other and ill-defined sites ingastrointestinal tract                         34                        29.6                        49         45.1         36         39.0         34         59.1       29.5     [\*](#nt108){ref-type="table-fn"}
  8.7 Carcinoma of other and ill-defined sites                                                    95                        41.3                       194         39.3        135         44.6        115         54.0       12.7     [\*](#nt108){ref-type="table-fn"}
  8.7.1 Adrenocortical carcinoma                                                                 N/S                                                                                                                                  
  8.7.2 Carcinoma of other and ill-defined sites, NOS                                             88                        40.0                       181         39.4        128         46.2         99         56.2       16.2     [\*](#nt108){ref-type="table-fn"}
  **9. Miscellaneous Specified Neoplasms, NOS**                                                **121**                    **54.0**                   **213**     **72.5**    **348**     **79.2**    **453**     **79.7**   **25.7**   [\*](#nt108){ref-type="table-fn"}
  9.1 Other pediatric and embryonaltumors, NOS                                                    33                        30.5                        43         46.7         51         57.0         51         63.1       32.6     [\*](#nt108){ref-type="table-fn"}
  9.2 Other specified and embryonal tumors, NOS                                                   88                        62.8                       170         79.1        297         83.0        402         81.7       18.9     [\*](#nt108){ref-type="table-fn"}
  **10. Unspecified Malignant Neoplasms**                                                      **546**                    **62.0**                   **714**     **70.8**    **339**     **79.0**    **235**     **77.8**   **15.8**   [\*](#nt108){ref-type="table-fn"}

\**P*-values \<0.05 for trend.

Change (%) in the 5-year RSR from 1993--1995 to 2006--2010.

Thyroid carcinoma was excluded from the calculation of the incidence rate of all cancers combined because of its unusually high incidence rate.

N/S: not shown because \<20 cases were reported in each period.

AYAs, adolescents and young adults (aged 15--29 years); CNS, central nervous system; PNET, primitive neuroectodermal tumor; NOS, not otherwise specified.

Survival rates for thyroid carcinoma (group 8.1) and skin carcinoma (group 7.2) were very high across all time periods. The five-year relative survival rate for thyroid carcinoma among males increased slightly, from 95.3% in 1993--1995 to 99.7% in 2006--2010, whereas the rate was unchanged among females from 1993--1995 (99.9%) to 2006--2010 (100.0%). The survival rates for germ cell and trophoblastic neoplasms (group 6), skin carcinoma (group 7.2), and carcinoma of the genitourinary tract (group 8.5) consistently exceeded 80--90% in all time periods. Conversely, the lowest survival rates were observed for rhabdomyosarcoma (group 5.2); carcinoma of the trachea, bronchus, and lung (group 8.3); and carcinoma of liver and intrahepatic bile ducts (group 8.6.3) ([Table 3](#pone-0096088-t003){ref-type="table"}).

The survival rates for all cancers combined significantly increased from 1993 to 2010 in both males and females. In particular, the 5-year relative survival rate increased from 46.5% to 75.9% in males (*P*\<0.05) and from 66.7% to 89.1% in females (*P*\<0.05). However, the 5-year relative survival rate for all cancers combined was slightly lower in males than in females, regardless of whether thyroid carcinoma was excluded ([Table 4](#pone-0096088-t004){ref-type="table"}).

10.1371/journal.pone.0096088.t004

###### Five-year RSRs for Korean AYAs according to the time period of cancer diagnosis and sex.

![](pone.0096088.t004){#pone-0096088-t004-4}

  Diagnostic group (SEER)                                                                        Males     Females                                                                                                                                                                                                                                                       
  ------------------------------------------------------------------------------------------- ----------- ---------- ----------- ---------- ----------- ---------- ----------- ---------- ---------- ----------------------------------- ----------- ---------- ----------------------------------- ---------- ----------- ---------- ------------ ---------- ---------- -----------------------------------
  **All Cancers**                                                                              **2,478**   **46.5**   **4,801**   **55.1**   **5,166**   **65.8**   **6,149**   **75.9**   **29.4**   [\*](#nt113){ref-type="table-fn"}   **3,909**   **66.7**               **7,652**               **73.6**   **9,144**   **82.6**   **12,778**   **89.1**   **22.4**   [\*](#nt113){ref-type="table-fn"}
  **All Cancers (excluding thyroid carcinoma)** [‡](#nt115){ref-type="table-fn"}               **2,366**   **44.2**   **4,516**   **52.4**   **4,696**   **62.3**   **4,924**   **70.5**   **26.3**   [\*](#nt113){ref-type="table-fn"}   **3,159**   **58.9**               **5,958**               **66.0**   **5,859**   **72.9**   **5,960**    **77.6**   **18.7**   [\*](#nt113){ref-type="table-fn"}
  **1. Leukemias**                                                                              **492**    **25.4**    **791**    **33.0**    **826**    **46.2**    **841**    **57.9**   **32.5**   [\*](#nt113){ref-type="table-fn"}    **374**    **26.3**                **649**                **39.4**    **571**    **49.8**    **594**     **60.0**   **33.7**   [\*](#nt113){ref-type="table-fn"}
  1.1 Acute lymphoid leukemia                                                                     140        22.3        253        27.4        236        30.2        272        49.2       26.9     [\*](#nt113){ref-type="table-fn"}      97         16.5                    180                    31.2        143        39.9        153         47.4       30.9     [\*](#nt113){ref-type="table-fn"}
  1.2 Acute myeloid leukemia                                                                      194        26.5        307        30.4        318        44.5        313        51.1       24.6     [\*](#nt113){ref-type="table-fn"}      181        25.5                    295                    44.8        306        50.1        275         54.7       29.2     [\*](#nt113){ref-type="table-fn"}
  1.3 Chronic myeloid leukemia                                                                    87         40.5        152        51.6        183        74.0        173        89.1       48.6     [\*](#nt113){ref-type="table-fn"}      54         42.7                    99                     50.6        69         81.3         89         93.2       50.5     [\*](#nt113){ref-type="table-fn"}
  1.4 Other and unspecified leukemia                                                              71         9.9         79         25.5        89         37.2        83         51.4       41.5     [\*](#nt113){ref-type="table-fn"}      42         31.0                    75                     22.7        53         34.0         77         67.3       36.3     [\*](#nt113){ref-type="table-fn"}
  **2. Lymphomas**                                                                              **262**    **50.7**    **558**    **60.9**    **637**    **72.8**    **748**    **80.9**   **30.2**   [\*](#nt113){ref-type="table-fn"}    **177**    **62.3**                **379**                **71.1**    **496**    **79.6**    **567**     **87.0**   **24.7**   [\*](#nt113){ref-type="table-fn"}
  2.1 Non-Hodgkin lymphoma                                                                        230        47.3        480        56.7        522        70.2        601        79.2       31.9     [\*](#nt113){ref-type="table-fn"}      142        57.9                    310                    66.6        384        75.7        436         85.9       28.0     [\*](#nt113){ref-type="table-fn"}
  2.2 Hodgkin lymphoma                                                                            32         75.5        78         86.3        115        84.6        147        87.3       11.8     [\*](#nt113){ref-type="table-fn"}      35         80.2                    69                     91.5        112        93.0        131         91.3       11.1     [\*](#nt113){ref-type="table-fn"}
  **3. CNS and Other Intracranial and Intraspinal Neoplasms**                                   **220**    **49.9**    **393**    **52.2**    **417**    **59.4**    **423**    **63.0**   **13.1**   [\*](#nt113){ref-type="table-fn"}    **151**    **58.4**                **296**                **57.6**    **313**    **60.8**    **327**     **68.9**   **10.5**   [\*](#nt113){ref-type="table-fn"}
  3.1. Astrocytoma                                                                                104        36.8        169        39.8        156        43.1        155        48.4       11.6                                            75         52.2                    136                    51.6        119        48.0        136         60.8       8.6     
  3.2 Other glioma                                                                                41         76.1        53         56.9        68         70.8        102        66.9       -9.2                                            24         66.9                    30                     70.2        73         61.8         75         77.0       10.1    
  3.3 Ependymoma                                                                                   5        100.6        32         84.8        28         86.0        39         94.0       -6.6                                             9         78.0                    17                     70.7        29         89.8         23         74.6       -3.4    
  3.4 Medulloblastoma and other PNET                                                               8         37.8        43         44.4        51         37.4        46         41.5       3.7                                             10         50.1                    41                     53.8        41         61.1         38         63.8       13.7    
  3.5 Other specified intracranial and intraspinal neoplasms                                      N/S                               N/S         \-                                                                                                                                                                                                                       
  3.6 Unspecified intracranial and intraspinal neoplasms                                          54         54.1        80         61.5        102        77.7        72         78.3       24.2     [\*](#nt113){ref-type="table-fn"}      28         57.3                    61                     60.8        43         72.2         46         84.3       27.0     [\*](#nt113){ref-type="table-fn"}
  **4. Osseous and Chondromatous Neoplasms**                                                    **163**    **48.8**    **317**    **65.0**    **290**    **66.1**    **296**    **74.7**   **25.9**   [\*](#nt113){ref-type="table-fn"}    **99**     **47.6**                **199**                **68.0**    **189**    **72.6**    **151**     **75.4**   **27.8**   [\*](#nt113){ref-type="table-fn"}
  4.1 Osteosarcoma                                                                                106        42.7        195        64.4        174        60.5        160        71.4       28.7     [\*](#nt113){ref-type="table-fn"}      54         44.6                    110                    67.4        107        73.0         71         74.6       30.0     [\*](#nt113){ref-type="table-fn"}
  4.2 Chondrosarcoma                                                                              17         71.1        43         86.5        44         93.5        44         93.5       22.4                                            11         54.7                    32                     87.7        25         76.2         33         96.4       41.7    
  4.3 Ewing tumor                                                                                 15         47.0        43         37.4        38         44.9        46         49.7       2.7                                             15         33.4                    23                     43.6        29         62.2         26         53.3       19.9    
  4.4 Other specified and unspecified bone tumors                                                 25         60.4        36         75.4        34         82.6        46         89.4       29.0     [\*](#nt113){ref-type="table-fn"}      19         63.3                    34                     67.8        28         78.7         21         77.1       13.8    
  **5. Soft Tissue Sarcomas**                                                                   **126**    **52.7**    **244**    **57.7**    **287**    **63.3**    **342**    **68.8**   **16.1**   [\*](#nt113){ref-type="table-fn"}    **117**    **65.1**                **237**                **60.1**    **267**    **72.1**    **275**     **78.6**   **13.5**   [\*](#nt113){ref-type="table-fn"}
  5.1 Fibromatous neoplasms                                                                       23         78.8        61         75.8        64         90.9        103        93.4       14.6     [\*](#nt113){ref-type="table-fn"}      28         78.8                    42                     81.1        71         96.0         90         96.7       17.9     [\*](#nt113){ref-type="table-fn"}
  5.2 Rhabdomyosarcoma                                                                            20         25.2        43         35.0        41         34.2        35         34.1       8.9                                             12         33.4                    30                     40.1        25         36.1         20         44.9       11.5    
  5.3 Other soft tissue sarcoma                                                                   83         52.2        140        56.7        182        60.1        204        62.8       10.6     [\*](#nt113){ref-type="table-fn"}      77         65.1                    165                    58.3        171        67.4        165         73.4       8.3     
  **6. Germ Cell and Trophoblastic Neoplasms**                                                  **98**     **72.9**    **323**    **79.3**    **457**    **85.8**    **574**    **88.8**   **15.9**   [\*](#nt113){ref-type="table-fn"}    **180**    **86.4**                **422**                **92.9**    **385**    **94.7**    **362**     **96.3**   **9.9**    [\*](#nt113){ref-type="table-fn"}
  6.1 Germ cell and trophoblastic neoplasms of gonads                                             47         90.0        157        85.8        255        90.5        331        95.4       5.4      [\*](#nt113){ref-type="table-fn"}      127        89.2                    308                    95.7        303        97.5        282         97.0       7.8      [\*](#nt113){ref-type="table-fn"}
  6.2 Germ cell and trophoblastic neoplasms of nongonadal sites                                   51         57.2        166        73.2        202        79.9        243        79.9       22.7                                            53         79.5                    114                    85.3        82         84.3         80         93.6       14.1    
  **7. Melanoma and Skin Carcinomas**                                                           **24**     **71.3**    **66**     **57.9**    **66**     **73.0**    **67**     **83.9**   **12.6**   [\*](#nt113){ref-type="table-fn"}    **32**     **59.6**                **45**                 **62.4**    **56**     **82.3**     **71**     **89.1**   **29.5**   [\*](#nt113){ref-type="table-fn"}
  7.1 Melanoma                                                                                    11         45.8        38         45.0        33         51.7        26         45.0       -0.8                                            14         21.5                    26                     42.4        30         70.1         33         76.5       55.0     [\*](#nt113){ref-type="table-fn"}
  7.2 Skin carcinomas                                                                             13         93.0        28         75.4        33         94.3        41         97.9       4.9                                             18         89.2                    19                     89.7        26         96.4         38        100.2       11.0    
  **8. Carcinomas**                                                                             **872**    **52.3**   **1,787**   **57.0**   **1,935**   **68.2**   **2,561**   **80.5**   **28.2**   [\*](#nt113){ref-type="table-fn"}   **2,333**   **73.1**               **4,820**               **77.9**   **6,431**   **86.6**   **10,040**   **92.4**   **19.3**   [\*](#nt113){ref-type="table-fn"}
  8.1 Thyroid carcinoma                                                                           112        95.3        285        97.3        470       100.2       1,225       99.7       4.4      [\*](#nt113){ref-type="table-fn"}      750        99.9                   1,694                   99.9       3,285       99.8       6,818       100.0       0.1     
  8.2 Other carcinoma of head and neck                                                            76         62.3        147        71.1        177        79.4        170        86.8       24.5     [\*](#nt113){ref-type="table-fn"}      64         78.4                    142                    84.7        162        87.2        163         84.5       6.1     
  8.2.1 Nasopharyngeal carcinoma                                                                  28         71.9        70         60.3        56         80.6        48         91.6       19.7     [\*](#nt113){ref-type="table-fn"}      12         66.9                    34                     76.7        23         78.4         27         77.6       10.7    
  8.2.2 Other sites in lip, oral cavity, and pharynx                                              32         72.4        65         86.6        108        79.9        112        86.6       14.2                                            41         85.6                    94                     88.5        125        90.5        123         90.3       4.7     
  8.2.3 Nasal cavity, middle ear, sinuses, larynx, and other ill-defined sites in head/neck       N/S                               N/S                                                                                                                                                                                                                                  
  8.3 Carcinoma of trachea, bronchus, and lung                                                    41         24.6        68         37.0        65         52.5        64         39.6       15.0                                            32         25.1                    68                     35.4        79         43.1         68         46.7       21.6     [\*](#nt113){ref-type="table-fn"}
  8.4 Carcinoma of breast                                                                         N/S                               309        67.9        686        77.3        822        81.9                    838                    86.6        18.7     [\*](#nt113){ref-type="table-fn"}                                                                       
  8.5 Carcinoma of genitourinary tract                                                            52         83.3        116        91.0        158        91.5        197        92.2       8.9                                             550        85.5                   1,075                   85.0       1,036       88.5       1,174        85.5        0      
  8.5.1 Carcinoma of kidney                                                                       14         79.2        43         86.5        85         89.8        129        91.9       12.7                                            21         62.1                    51                     68.8        57         84.4         80         78.8       16.7     [\*](#nt113){ref-type="table-fn"}
  8.5.2 Carcinoma of bladder                                                                      30         87.3        61         95.6        61         95.4        60         95.0       7.7                                             N/S                                                                                                                         
  8.5.3 Carcinoma of gonads                                                                       N/S                               231        86.8        392        84.4        324        88.1                    290                    82.6        -4.2                                                                                                             
  8.5.4 Carcinoma of cervix and uterus                                                            N/S                               285        86.6        605        86.7        611        89.1                    781                    87.0        0.4                                                                                                              
  8.5.5 Carcinoma of other and ill-defined sites in genitourinary tract                           N/S                               N/S                                                                                                                                                                                                                                  
  8.6 Carcinoma of gastrointestinal tract                                                         536        43.1       1,064       43.0        984        49.4        842        56.5       13.4     [\*](#nt113){ref-type="table-fn"}      587        33.3                   1,063                   41.5        990        51.0        924         61.7       28.4     [\*](#nt113){ref-type="table-fn"}
  8.6.1 Carcinoma of colon and rectum                                                             140        51.1        299        50.1        287        62.6        330        73.6       22.5     [\*](#nt113){ref-type="table-fn"}      106        41.6                    228                    56.3        213        64.0        273         74.6       33.0     [\*](#nt113){ref-type="table-fn"}
  8.6.2 Carcinoma of stomach                                                                      307        44.0        530        48.0        445        51.9        310        56.5       12.5     [\*](#nt113){ref-type="table-fn"}      416        30.6                    709                    36.5        646        47.0        521         59.3       28.7     [\*](#nt113){ref-type="table-fn"}
  8.6.3 Carcinoma of liver and intrahepatic bile ducts                                            62         26.0        193        19.3        226        28.4        170        31.4       5.4      [\*](#nt113){ref-type="table-fn"}      28         17.9                    84                     33.4        82         47.7         86         31.4       13.5    
  8.6.4 Carcinoma of pancreas                                                                     N/S                                21        66.9         18        83.5         24        71.0                    28                     69.3        2.4                                                                                                              
  8.6.5 Carcinoma other and ill-defined sites in gastrointestinal tract                           18         28.0        25         44.3        11         45.6        18         45.3       17.3                                            16         31.3                    24                     46.0        25         36.1         16         75.2       43.9     [\*](#nt113){ref-type="table-fn"}
  8.7 Carcinoma of other and ill-defined sites                                                    54         31.7        102        44.3        78         51.5        60         48.1       16.4     [\*](#nt113){ref-type="table-fn"}      41         53.8                    92                     33.8        57         35.2         55         60.2       6.4     
  8.7.1 Adrenocortical carcinoma                                                                  N/S                               N/S                                                                                                                                                                                                                                  
  8.7.2 Carcinoma of other and ill-defined sites, NOS                                             51         33.6        94         44.9        76         51.5        53         48.7       15.1     [\*](#nt113){ref-type="table-fn"}      37         48.8                    87                     33.4        52         38.5         46         66.1       17.3    
  **9. Miscellaneous Specified Neoplasms, NOS**                                                 **51**     **49.4**    **80**     **52.8**    **154**    **71.0**    **221**    **81.0**   **31.6**   [\*](#nt113){ref-type="table-fn"}    **70**     **57.3**                **133**                **84.4**    **194**    **85.7**    **232**     **78.6**   **21.3**  
  9.1 Other pediatric and embryonal tumors, NOS                                                   21         33.6        24         33.5        32         53.3        27         62.6       29.0     [\*](#nt113){ref-type="table-fn"}      12         25.1                    19                     63.3        19         63.3         24         63.4       38.3    
  9.2 Other specified and embryonal tumors, NOS                                                   30         60.4        56         61.0        122        75.6        194        83.4       23.0     [\*](#nt113){ref-type="table-fn"}      58         64.0                    114                    87.9        175        88.2        208         80.3       16.3    
  **10. Unspecified Malignant Neoplasms**                                                       **170**    **40.9**    **242**    **56.1**    **97**     **64.2**    **76**     **70.7**   **29.4**   [\*](#nt113){ref-type="table-fn"}    **376**    **71.5**                **472**                **78.4**    **242**    **84.9**    **159**     **81.3**   **9.8**    [\*](#nt113){ref-type="table-fn"}

\**P*-values \<0.05 for trend.

Change (%) in the 5-year RSRs from 1993--1995 to 2006--2010.

Thyroid carcinoma was excluded from the incidence rate of all cancers combined because of its unusually high incidence rate.

N/S: not shown because \<20 cases were reported in each period.

AYAs, adolescents and young adults (aged 15--29 years); CNS, central nervous system; PNET, primitive neuroectodermal tumor; NOS, not otherwise specified.

Leukemia (group 1) showed the greatest increase in survival in both males (32.5%) and females (33.7%). In particular, chronic myeloid leukemia had the largest and second-largest increases in survival in males (48.6%; from 40.5% to 89.1%) and females (50.5%; from 42.7% to 93.2%), respectively.

[Figure 2](#pone-0096088-g002){ref-type="fig"} depicts the 5-year relative survival rates of all cancer patients in each of the four time periods according to age (15--19 years, 20--24 years and 25--29 years) and sex. Both gender, the 5-year relative survival rates increased in all age groups. For males aged 15--19 years, the 5-year relative survival rates in 1993--1995, 1996--2000, 2001--2005, and 2006--2010 for all cancers combined were 45.3% (95.% CI: 41.2--49.2), 55.4% (95% CI: 52.5--58.1), 65.3% (95% CI: 62.5--67.9), and 72.2% (95% CI: 69.2--75.0), respectively. The survival rates of males aged 20--24 years were 43.9% (95% CI: 40.2--47.5), 55.0% (95% CI: 52.2--57.7), 65.0% (95% CI: 62.5--67.3), and 77.0% (95% CI: 74.3--79.5) in 1993--1995, 1996--2000, 2001--2005, and 2006--2010, respectively. The survival rates of males aged 25--29 years were 48.8% (95% CI: 45.9--51.7), 55.0% (95% CI: 52.9--57.0), 66.5% (95% CI: 64.6--68.3), and 77.2% (95% CI: 75.3--79.0) in 1993--1995, 1996--2000, 2001--2005, and 2006--2010, respectively. For females aged 15--19 years, the 5-year relative survival rates for all cancers combined were 62.0% (95% CI: 58.0--65.8), 72.0% (95% CI: 69.4--74.5), 78.8% (95% CI: 76.3--81.0), and 82.2% (95% CI: 79.7--84.5) in 1993--1995, 1996--2000, 2001--2005, and 2006--2010, respectively. The survival rates of females aged 20--24 years were 67.4% (95% CI: 64.6--70.1), 74.4% (95% CI: 72.4--76.3), 83.7% (95% CI: 82.2--85.1), and 88.9% (95% CI: 87.4--90.2) in 1993--1995, 1996--2000, 2001--2005, and 2006--2010, respectively. The survival rates of females aged 25--29 years were 67.7% (95% CI: 65.7--69.6), 73.6% (95% CI: 72.2--74.9), 82.9% (95% CI: 81.9--83.9), and 90.4% (95% CI: 89.5--91.2) in 1993--1995, 1996--2000, 2001--2005, and 2006--2010, respectively.

![Trends in relative survival after cancer in Korea according to age and the time period.](pone.0096088.g002){#pone-0096088-g002}

Discussion {#s4}
==========

This is the first study to investigate cancer incidence, survival and their trends among AYAs using the population-based national cancer registry in Korea. The major findings of this study were that cancer in AYAs showed a trend of increasing incidence, with an increase of 6.3% per year (*P*\<0.05), from 1999 to 2010 and that age- and gender-related cancer incidence patterns differed according to the primary site. Moreover, five-year relative survival rates for most cancers improved from 1993--1995 (58.9%) to 2006--2010 (84.8%) among AYAs.

When comparing our study with studies from other countries, cancer incidence rates among AYAs in our study were lower than incidence rates in the U.S. [@pone.0096088-Bleyer2], France [@pone.0096088-Desandes1], Portugal [@pone.0096088-Carreira1], and Netherlands [@pone.0096088-Aben1] and among males in Canada [@pone.0096088-Canadian1], even though the time period and age group differs. In other studies, cancer incidence in AYA males was generally similar to or higher than cancer incidence in AYA females. Conversely, we reported much lower incidence rates in males than in females. The reason for this difference in the incidence rate by gender was that thyroid carcinoma has the highest incidence and rapidly increased in incidence among AYA females in Korea.

Consistent with other studies, we found a rising incidence of cancer among AYAs during the study period.

The data on AYAs in Korea reported here exhibited several important differences from site-specific cancer incidence rates among AYAs in other regions of the world. Since the 2000s, an annual increase in incidence of 0.6--2.0% has been reported in several countries [@pone.0096088-Howlader1], [@pone.0096088-Alston1]--[@pone.0096088-Haggar1]. However, our results showed an annual increase in incidence of 6.3%, which is a more rapid increase than observed in other studies. The increased cancer incidence rate may be partially explained by changes in cancer classification, as exemplified by changes in the classification of hematologic malignancies in a study by Park et al. [@pone.0096088-Park1].

The increased incidence of carcinomas was primarily due to an increase in the incidence rates of thyroid carcinoma (APC = 17.9%). An increased incidence rate of thyroid carcinoma has also been noted among AYAs in Western countries [@pone.0096088-Alston1], [@pone.0096088-Marrett1], [@pone.0096088-Hogan1]. However, the incidence of thyroid carcinoma among AYAs is more than three- to tenfold higher in Korea than in Canada [@pone.0096088-Canadian1], England [@pone.0096088-Alston1], the United States [@pone.0096088-Bleyer2], the Netherlands [@pone.0096088-Aben1] and Portugal [@pone.0096088-Carreira1]. The reasons for the high incidence of thyroid carcinoma in Korean AYAs compared with other nationalities are unknown. Although the rapid increase and high incidence rate of thyroid cancer among older individuals worldwide might be attributable to the development of improved technologies for early detection [@pone.0096088-Davies1], the exact cause of the increased incidence of most cancers in AYAs is unknown. Because of the difficulty in recommending thyroid cancer screening for AYAs solely based on incidence rates, further research to identify associated risk factors, such as family history, socioeconomic status, and environmental exposure, is needed.

In this study, a notable trend of increasing incidence was also observed for cervical carcinoma (APC = 6.2%) among female AYAs in Korea. Although the incidence of cervical carcinoma in Korean females of all ages is decreasing (APC  =  −4.3%) [@pone.0096088-Jung1], the incidence of cervical carcinoma has been increasing among Korean females under 30 years of age [@pone.0096088-Oh1]. A steady increase in cervical carcinoma in young women (20--29 years) has also been observed in England [@pone.0096088-Patel1]. The increased incidence of cervical carcinoma among AYAs has been attributed to increases in human papillomavirus (HPV) infection [@pone.0096088-Kim1], [@pone.0096088-Han1]. More specifically, an increase in sexual behavior among younger age groups has led to an increased rate of HPV infection [@pone.0096088-Vaccarella1], [@pone.0096088-Shin2], and the prevalence rate of HPV has been reported to increase with decreasing age [@pone.0096088-Kim1]. Therefore, since 2007, the Korean Society of Gynecologic Oncology and Colposcopy (KSGOC) has recommended the HPV vaccine for females aged 15--17 for the prevention of cervical carcinoma. In fact, certain recent studies have reported a decrease in the incidence of cervical carcinoma due to the use of the HPV vaccine at an earlier age [@pone.0096088-Cuzick1], [@pone.0096088-Barnabas1]. Therefore, the incidence of cervical carcinoma is expected to gradually decline among AYAs in Korea due to the HPV vaccine.

In terms of survival, our data are consistent with that reported for other geographic regions. Although the time period in our study differed, the overall cancer survival rate among AYAs in Korea was similar to the rate and significantly improvement reported in the U.S. and Germany. Improvements in relative survival rates among AYAs can be partially explained by advances in cancer detection, more intensive treatments, and increased expertise in adolescent oncology [@pone.0096088-Barr2]. Additionally, access to effective protocols and the development of health infrastructures may have also contributed to improvements in survival rates [@pone.0096088-PritchardJones1].

However several important differences should be highlighted in lymphoma and leukemia. In the present study, the most significant improvements in survival were observed in leukemia and lymphoma patients, but the survival rates for leukemia and lymphoma were noticeably lower than in the U.S. and Germany [@pone.0096088-SteliarovaFoucher1], [@pone.0096088-Gondos1]. This reason for this difference in the survival rate by ethnic was that the incidence cases of subgroup of leukemia and lymphoma was different between U.S. AYAs [@pone.0096088-Gondos1] and Korea AYAs. More, ethnic disparities in tumor biology and clinical factors may influence cancer treatment and survival [@pone.0096088-Shavers1].

Compared with the survival of patients aged 1 to 10 years, overall survival and disease-specific survival are clinically significantly poorer among AYA patients with acute lymphoblastic leukemia [@pone.0096088-Tricoli1]. The survival rates for leukemia among the Korean AYAs in our study have remained worse than among Korean children based on data from the KCCR [@pone.0096088-The1].

Among AYAs, breast cancer accounts for approximately 7% and 4.9% of all cancers diagnosed in the United States [@pone.0096088-Bleyer2] and Korea, respectively. In the United States, the 5-year survival rate for breast cancer is lower among AYAs (80.2%) than among patients in other age groups (30--39 years, 83.4%; 40--49 years, 88.9%), and particularly older patients [@pone.0096088-Gondos1]. Our study showed similar results. The relative survival rate for breast cancer among Korean females aged 15--29 years was 86.8% in 2006--2010, whereas the relative survival rate among Korean females aged ≥40 years was 91.0% based on a direct estimate from the KNCIDB.

One limitation of our study is that the follow-up period began relatively soon after the diagnosis of cancer, in contrast to the protocols in other studies [@pone.0096088-Aben1]--[@pone.0096088-Bleyer2]. Another limitation of this study is that we could not estimate the survival rates after adjusting for cancer stage and treatment because our registry database did not include information on cancer stage and treatment.

In conclusion, our study provides representative cancer statistics regarding temporal trends in the AYA population in Korea. In particular, the results showed an increasing trend in cancer incidence and an improving survival trend among AYAs in Korea. These results may support cancer control and prevention plans focusing on AYAs.

In the future, further research will help to identify factors affecting cancer incidence and responses to treatment among AYAs. In particular, research on the etiological factors related to the rapid increase in thyroid carcinoma in AYAs is needed.
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